ALNYLAM PHARMACEUTICALS, INC. Research and Development Asset Acquired Other than Through Business Combination, Written-off
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $220.77 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2017-02-15
- ALNYLAM PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2014-12-31 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for the quarter ending 2014-03-31 was $224.66M.
- ALNYLAM PHARMACEUTICALS, INC. research and development asset acquired other than through business combination, written-off for fiscal 2014 was $220.77M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $220.77M 10-K · filed 2017-02-15 | ||
| 2014-09-30 | $220.77M 10-Q · filed 2015-11-09 | |||
| 2014-03-31 | $224.66M 10-Q · filed 2015-05-08 | |||
| 2014-03-05 | $199.30M 10-K · filed 2016-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |